{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Previously untreated metastatic colorectal cancer"],"disease":["Previously Untreated Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2518837"],"location":["United Kingdom"],"study_start_month":["5"],"keyword":["Xeloda","Mitomycin-C","Avastin"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"The MAX study: A randomised phase II/III study to evaluate the role of Mitomycin C, Avastin and Xeloda in patients with untreated metastatic colorectal cancer","description":"Primary objectives: Phase II stagePrimary Objective:• To determine the relative toxicity of the combination of capecitabine andbevacizumab and the combination of capecitabine, mitomycin C (MMC) andbevacizumab with that of capecitabine monotherapy.\nPhase III stagePrimary Objective:• To compare progression-free survival (PFS) on the three arms\nPrimary endpoints: Phase II stagePrimary Endpoint: Treatment-related toxicity\nPhase III stagePrimary endpoint: Progression free survival (PFS)","dates":{"creation":"2006-05-15"},"accession":"2518837","cross_references":{"EU Clinical Trials Register":["2005-005761-11"]}}